David C. Budd

Trinity Health — United States

Medicine · Health Sciences

29h-index3.1kcitations95works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pulmonary Hypertension Research and Treatments(16), Receptor Mechanisms and Signaling(15), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(11), Protein Kinase Regulation and GTPase Signaling(8), Dementia and Cognitive Impairment Research(7)

Publications95 total

EE315 Cost-Effectiveness of Obicetrapib As Adjunctive Therapy Compared to Maximally Tolerated Statins for Lowering LDL-c
Value in Health·2024Open Access
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Dermatology and Therapy·2024· 15 citedOpen Access
S73 Single cell RNA sequencing of PBMCs reveals differences between fast and slow resolving post-COVID interstitial lung disease
2023Open Access
Study to Explore the Association of the Renin-Angiotensin System and Right Ventricular Function in Mechanically Ventilated Patients
Journal of Clinical Medicine·2022Open Access
An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
Pulmonary Circulation·2021· 14 citedOpen Access
Effects of Recombinant Human Angiotensin-Converting Enzyme 2 on Response to Acute Hypoxia and Exercise: A Randomised, Placebo-Controlled Study
Pulmonary Therapy·2021· 5 citedOpen Access
Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis
Pulmonary Pharmacology & Therapeutics·2018· 50 cited
Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA
Current Medical Research and Opinion·2017· 21 cited
Correction to “Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma”
ACS Medicinal Chemistry Letters·2017· 1 citedOpen Access
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma
ACS Medicinal Chemistry Letters·2017· 31 citedOpen Access
Discovery of Fevipiprant (NVP-QAW039), a potent and selective CRTh2 receptor antagonist for treatment of allergic diseases
2017
Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA
Figshare·2017Open Access
P112 &lt;break /&gt; Discovery of a Novel, High Affinity, Small Molecule αvβ6 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
QJM·2016· 8 citedOpen Access
Transforming Growth Factor Beta Gene Signatures are Spatially Enriched in Keloid Tissue Biopsies and Ex vivo-Cultured Keloid Fibroblasts
Acta Dermato Venereologica·2016· 15 citedOpen Access
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature
Journal of Medicinal Chemistry·2016· 72 citedOpen Access
Resource Utilization And Treatment Costs Of Stroke In Patients With Non-Valvular Atrial Fibrillation In Spain
Value in Health·2015
Persistence To Vitamin-K Antagonists (Vka) And Novel Oral Anticoagulants (Noacs) In Non-Valvular Atrial Fibrillation (Nvaf): An Observational Study Using A Comprehensive Regional Database In Catalonia, Spain
Value in Health·2015· 3 cited
FRI0348 Cost Comparison of Abatacept and Adalimumab Based on Ample, A 2-Year Head-to-Head Outcomes Study in Rheumatoid Arthritis
Annals of the Rheumatic Diseases·2015· 2 cited
Comparison of “Word” vs. “Picture” version of the Free and Cued Selective Reminding Test (FCSRT) in older adults
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring·2015· 35 citedOpen Access
Identification of a novel class of autotaxin inhibitors through cross-screening
MedChemComm·2015· 8 cited
page 1 of 5Next →

Frequent Co-authors

Alan Holmes(9), Christoph Walker(8), Andrew B. Tobin(8), Christopher S. Stevenson(6), Nicholas W. Morrell(5), David G. Nicholls(5), Yonglin Ren(5), María E. Fuentes(5), Ruoqi Peng(4), Yimin Qian(4), David A. Sandham(4), Lucy Barker(4), Zarin Brown(4), Gerald Dubois(4), Brian J. Cox(4), Jodie Manini(4), Rachael Profit(4), Rowan Stringer(4), Katharine L. Turner(4), Jennifer Willis(4)